Muscular Dystrophy Canada Statement on Collaboration with Novartis for National Newborn Screening in Spinal Muscular Atrophy (SMA)
This past week, Muscular Dystrophy Canada (MDC) released a statement from Stacey Lintern, Chief Executive Officer of MDC on a Collaboration with Novartis for National Newborn Screening in Spinal Muscular Atrophy (SMA).
Statement from Dr. Hanns Lochmüller, Lead Investigator for NMD4C:
“We are thrilled to see our partners MDC collaborating with Novartis Pharmaceuticals Canada Inc to implement newborn screening as a standardized procedure across Canada. The strong national network of patient organizations, medical experts, researchers, and other stakeholders combined with investment from Novartis is a robust foundation on which to develop a national newborn screening plan.”
For many neuromuscular disorders, early diagnosis and prompt access to treatments are integral in achieving positive outcomes.
Unfortunately, this is not the reality for many patients who do not receive diagnoses until much later. For children born with Spinal Muscular Atrophy (SMA), newborn screening can identify children in need of treatment and care, which can drastically increase their chances of positive developmental outcomes.
Read next...
Save the Date: 2027 NMD4C-RARE.Qc Basic Science Research Summer School
NMD4C and RARE.Qc are pleased to announce the 2027 NMD4C–RARE.Qc Basic Science Research Summer School, will take place May 12-14, 2027, at the Université du Québec à Trois-Rivières (UQTR). The Summer School will bring together graduate students, postdoctoral fellows, and early-career researchers for hands-on training workshops, scientific lectures, trainee presentations, networking opportunities, and engagement with leading experts in neuromuscular and rare disease research.
Now Open: 2027 Postdoctoral Research Fellowship Funding Competition
Deadline: Oct 14 2026 | We are happy to announce that applications for the 2027 Postdoctoral Research Fellowship Funding Competition, in partnership with Muscular Dystrophy Canada, is now open. This annual funding competition awards salary support to early-career scientists in interested in advancing their postdoctoral studies in neuromuscular disease (NMD) research.
Congratulations to our 2026 Collaborative Research Training Award Recipients!!!
We are excited to announce the recipients of the 2026 NMD4C Collaborative Research Training Awards, which supports Canadian trainees in their efforts to advance neuromuscular disease research while strengthening national collaboration among neuromuscular research laboratories.